Hepatology Resource Center
DAAs do not increase risk of hepatic decompensation in HCV patients February 20, 2017By Mark L. FuerstResearchers say theirs is first national study with a large population to examine possible link. DAA therapy effective in advanced liver disease in real-world study February 20, 2017By Mark L. FuerstAll-oral sofosbuvir-based therapy proves a significant advance for hepatitis C virus patients. Researchers unveil optimal timing of HCV therapy in transplantation January 24, 2017By Mark FuerstA new study by Yale researchers reveals the optimal timing for hepatitis C virus therapy in patients eligible for a liver transplant. Oral DAA combination found effective in HCV patients January 24, 2017By Mark FuerstDirect-acting antiviral combination “represents an excellent treatment option” in some cases, says study’s senior author. DAAs aid treatment of hepatitis C patients with cancer December 01, 2016By Mark L. FuerstDirect-acting antiviral agents can be safely administered with chemotherapy in patients with hepatitis C virus, according to new research. DAA treatment restricted for Canadian hepatitis C patients December 01, 2016By Mark L. FuerstPatients with hepatitis C virus (HCV) in Canada are limited in their access to direct-acting antiviral agents, according to researchers. Liver distress: Top 10 care and cost concerns
December 01, 2016This slide show highlights the top 10 issues we covered this year on managing treatment of patients with HCV infection.
HCV patients on DAAs need hepatitis B testing November 03, 2016By Mark L. FuerstA test for hepatitis B virus should be done for patients beginning treatment with direct-acting antiviral therapy for their hepatitis C, experts advise. DAA therapies can reduce overall HCV treatment costs November 03, 2016By Mark L. FuerstA new study shows all-oral direct-actin antiviral agents for hepatitis C can provide both short- and long-term economic value. HCV patient cost sharing for DAAs does not make sense October 03, 2016By Mark L. FuerstInsurance arrangements for direct-acting antivirals, where hepatitis C virus patients share the burden of treatment costs, are ineffective says one researcher.